Evaluation after unprovoked VTE (occult cancer screening)
Applied
Type
ReinforcementConfidence
90%
Created
Mar 19, 2026
Evidence
1 source
Rationale
The integration of Patel (2022) reinforces the existing recommendations derived from the SOME trial. It provides updated epidemiological context (the 4-5% incidence rate) and confirms that the standard of care remains limited, age-appropriate screening rather than extensive imaging, which aligns with the current textbook content. Abbreviations were expanded per instructions.
Evidence
Content Changes
removedadded
The optimal approach to cancer screening after unprovoked venous thromboembolism (VTE) remains an area of clinical uncertainty. Current evidence supports limited age-appropriate cancer screening rather than routine extensive imaging.imaging [@patel2022]. The SOME (Screening for Occult Malignancy in patients with idiopathic venous thromboembolism) trial demonstrated that routine CTcomputed tomography (CT) imaging of the abdomen and pelvis does not improve cancer detection rates or patient outcomes compared to standard age-appropriate screening in patients with unprovoked VTE. The incidence of occult malignancy is estimated at approximately 4% to 5% within the first year following the VTE event [@patel2022]. Therefore, the recommended approach consists of: comprehensive history and physical examination, basic laboratory tests (complete blood count,count (CBC), chemistry), and age-appropriate cancer screening (colonoscopy, mammography, Pap smear, prostate-specific antigen)antigen (PSA)) as per standard guidelines. Extensive imaging or invasive testing should be reserved for patients with abnormal findings on initial evaluation or specific clinical suspicion [@rodger2015].